MRKMerck Sharp & Dohme LLCRunning, no new patients
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
Papillomavirus Infections
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 8,100 (planned)
- Started
- Feb 18, 2022
- Main results expected
- May 25, 2029
- Fully finished
- May 25, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Stage I: Combined Incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related External Genital and Intra-anal 12-month Persistent Infection
Measured over: Up to approximately 30 months
Stages I and II: Combined Incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related Genital Warts, PIN, or Penile/Perianal/Perineal Cancer
Measured over: Up to approximately 78 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05285826 · record last updated 2024-12-16 · checked 2026-11-09 15:47 UTC